The Oncology Institute, Inc. (TOI) — Financial statements
Income statement, balance sheet, and cash flow for The Oncology Institute, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 503↑27.8% | 393↑21.3% | 324↑28.4% | 252↑24.4% | 203 | |
| Cost of Revenue | 426↑25.6% | 339↑28.2% | 265↑32.1% | 200↑23.6% | 162 | |
| Gross Profit | 76↑41.6% | 54↓9.4% | 60↑14.4% | 52↑27.5% | 41 | |
| Operating Expenses | ||||||
| R&D Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 106 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Expenses | 7↓93.9% | 114↓16.5% | 137↑1.9% | 134↑54.6% | 87 | |
| Operating Expenses | 113↓1.4% | 114↓16.5% | 137↑1.9% | 134↑54.6% | 87 | |
| Total Costs & Expenses | 539↑18.8% | 454↑13.0% | 401↑20.0% | 334↑34.4% | 249 | |
| Operating Results | ||||||
| Operating Income | -36↑40.0% | -60↑21.9% | -77↑6.0% | -82↓78.7% | -46 | |
| Depreciation & Amortization | 7↑10.5% | 6↑7.0% | 6↑33.1% | 4↑32.0% | 3 | |
| EBITDA | -43↑21.0% | -54↑0.8% | -54↑19.7% | -68↓60.8% | -42 | |
| EBIT | -49↑17.7% | -60↑0.1% | -60↑16.5% | -72↓58.7% | -45 | |
| Interest & Other Income | ||||||
| Net Interest Income | -11↓50.4% | -7↓10.6% | -7↓66.0% | -4↓1175.6% | -0.32 | |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 11↑50.4% | 7↑10.6% | 7↑66.0% | 4↑1175.6% | 0.32 | |
| Non-Operating Income | 13 | 0.00↑100.0% | -17↓69.6% | -10↓1989.1% | -0.48 | |
| Other Income / Expenses | -25↓442.4% | -5↑25.3% | -6↓107.4% | 82↑138.9% | 34 | |
| Income Before Tax | -61↑6.1% | -65↑22.2% | -83↓91223.1% | -0.09↑99.2% | -12 | |
| Income Tax Expense | -0.13 | 0.00↑100.0% | -0.04↑85.2% | -0.24↑63.8% | -0.67 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -61↑6.3% | -65↑22.2% | -83↓54750.0% | 0.15↑101.4% | -11 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -61↑6.3% | -65↑22.2% | -83↓54750.0% | 0.15↑101.4% | -11 | |
| Bottom-Line Net Income | -50↑5.1% | -53↑21.9% | -68↓299.7% | -17↓59.8% | -11 | |
| EPS (Basic) | -0.54↑23.9% | -0.71↑22.8% | -0.92↓102322.2% | 0.00↑100.6% | -0.16 | |
| EPS (Diluted) | -0.54↑23.9% | -0.71↑22.8% | -0.92↓338.1% | -0.21↓31.2% | -0.16 | |
| Weighted Average Shares | 924↑1131.1% | 75↑1.8% | 74↑1.3% | 73↑9.9% | 66 | |
| Weighted Average Diluted Shares | 924↑1131.1% | 75↑1.8% | 74↓8.5% | 81↑21.7% | 66 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.